详细信息
Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis ( SCI-EXPANDED收录)
文献类型:期刊文献
英文题名:Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis
作者:Zhang, Zhihong[1,2];Wu, Guotai[2,3];Yang, Jie[1,4];Liu, Xuxia;Chen, Zhengjun[1];Liu, Dongling[3];Huang, Yan[5];Yang, Fude[1];Luo, Wenrong[6]
第一作者:Zhang, Zhihong;张志红
通信作者:Yang, FD[1];Luo, WR[2]
机构:[1]Gansu Univ Chinese Med, Sch Pharm, Lanzhou 730101, Peoples R China;[2]Gansu Key Lab Pharmacol & Toxicol Tradit Chinese M, Lanzhou 730000, Peoples R China;[3]Long Yao Ind Innovat Res Inst, Lanzhou 730000, Peoples R China;[4]Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China;[5]Lanzhou Univ, Hosp 2, Dept Pharm, Lanzhou 730030, Peoples R China;[6]Gansu Prov Hosp Tradit Chinese Med, Lanzhou 730050, Peoples R China
第一机构:甘肃中医药大学
通信机构:[1]corresponding author), Gansu Univ Chinese Med, Sch Pharm, Lanzhou 730101, Peoples R China;[2]corresponding author), Gansu Prov Hosp Tradit Chinese Med, Lanzhou 730050, Peoples R China.|[10735]甘肃中医药大学;
年份:2025
卷号:337
外文期刊名:JOURNAL OF ETHNOPHARMACOLOGY
收录:;WOS:【SCI-EXPANDED(收录号:WOS:001322204800001)】;
语种:英文
外文关键词:Danggui-Baishao herb pair (DB); Hepatic fibrosis; Network pharmacology; Transcriptomics; Metabolomics
摘要:Ethnopharmacological relevance: The Danggui-Baishao herb pair (DB) is commonly used as Chinese herbal formulas for treating hepatic fibrosis (HF). However, there are few research on the combined application of the two drugs in treating HF, and the precise mechanisms and fundamental components of DB in addressing HF are still unclear. Aim of the study: The intention of this research is to identify the molecular foundation and functional targets of DB to elucidate the mechanisms for treating HF. Methods: The ingredients absorbed from DB in rat plasma were analyzed using UPLC-QE-MS. Therapeutic efficacy of DB in a rat model of CCl4-induced HF assessed using biochemical indices, pathological tissue observations, immunohistochemical and western blotting. An integrated strategy of transcriptomics, metabolomics, and network pharmacology was then utilized to explain the possible material basis and mechanisms of DB for treating HF. Western blotting was carried out to verify the critical mechanism. Results: DB reduced the level of liver function and inflammation related indicators in CCl4-induced HF (P < 0.05 or P < 0.01), as well as ameliorated pathological histological changes, and reduced the expressions of collagen type I (Col-I) and alpha-smooth muscle actin (alpha-SMA). Nineteen ingredients absorbed from DB were identified. Comprehensive investigations of transcriptomics, metabolomics, and network pharmacology revealed that DB modulated the PI3K/Akt/NF-kappa B signaling pathway to ameliorate fibrosis induced by CCl4 in HF rats. According to the molecular docking results, core tagets were highly favored by kaempferol, benzoylpaeoniflorin, albiflorin, paeoniflorin, and levistilide A. Conclusions: The possible mechanisms for DB treatment of HF include decreasing the activity of hepatic stellate cells (HSCs), decreasing collagen synthesis and deposition, attenuating the hepatic inflammatory response, inhibiting hepatocyte apoptosis, and increasing the level of niacinamide (NAM), thus exerting its anti-HF effect.
参考文献:
正在载入数据...